Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia

Cancer Immunology, Immunotherapy

Volumn 57, Issue 11, 2008, Pages 1705-1710

  Palma, M ^a   Adamson, L ^a   Hansson, L ^a   Kokhaei, P ^a   Rezvany, R ^a   Mellstedt, H ^a   Osterborg A ^a   Choudhury, A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Clinical trial; CLL; Dendritic cell; Immunotherapy; T cell

Indexed keywords

CD14 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKINE; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY;

CANCER IMMUNOTHERAPY; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CRYOPRESERVATION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; IMMUNOGENICITY; IMMUNOMAGNETIC SEPARATION; IMMUNOSTIMULATION; LEUKAPHERESIS; LOW DRUG DOSE; MONOLAYER CULTURE; PATIENT MONITORING; PHENOTYPE; PRIORITY JOURNAL; THAWING; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

EID: 50649112582     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0561-y     Document Type: Conference Paper

References (44)

1. L Adamson A Palmborg A Svensson 2004 Development of a technology platform for large-scale clinical grade production of DC Cytotherapy 6 363 371
2. M Beyer M Kochanek K Darabi 2005 Reduced frequencies and suppressive function of CD4+ CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine Blood 106 2018 2025
3. E Biagi R Rousseau E Yvon 2005 Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia Clin Cancer Res 11 6916 6923
4. R Buhmann A Nolte D Westhaus 1999 CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells Blood 93 1992 2002
5. C Butts N Murray A Maksymiuk 2005 Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer J Clin Oncol 23 6674 6681
6. JC Byrd K Rai BL Peterson 2005 Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011 Blood 105 49 53
7. CM Counter J Gupta CB Harley 1995 Telomerase activity in normal leukocytes and in hematologic malignancies Blood 85 2315 2320
8. LD Cranmer KT Trevor EM Hersh 2004 Clinical applications of dendritic cell vaccination in the treatment of cancer Cancer Immunol Immunother 53 275 306
9. J Dannull Z Su D Rizzieri 2005 Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells J Clin Invest 115 3623 3633
10. RO Dillman SR Selvan PM Schiltz 2006 Patient-specific dendritic-cell vaccines for metastatic melanoma N Engl J Med 355 1179 1181
11. G Dranoff 2002 GM-CSF-based cancer vaccines Immunol Rev 188 147 154
12. P Dreger R Brand D Milligan 2005 Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis Leukemia 19 1029 1033
13. BF Eichhorst R Busch G Hopfinger 2006 Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia Blood 107 885 891
14. K Giannopoulos I Hus L Li 2005 The receptor for hyaluronic acid mediated motility (RHAMM/CD168) is a potential target for immunotherapy of patients with B-cell chronic lymphocytic leukemia Blood 106 11 53
15. JG Gribben D Zahrieh K Stephans 2005 Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia Blood 106 4389 4396
16. M Hallek BD Cheson D Catovsky 2008 Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines Blood 111 12 5446 5456
17. TJ Hamblin Z Davis A Gardiner 1999 Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia Blood 94 1848 1854
18. S Harig M Witzens AM Krackhardt 2001 Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues Blood 98 2999 3005
19. DS Hoon LJ Foshag AS Nizze 1990 Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide Cancer Res 50 5358 5364
20. I Hus J Rolinski J Tabarkiewicz 2005 Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia Leukemia 19 1621 1627
21. I Hus M Schmitt J Tabarkiewicz 2008 Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+ CD25+ FoxP3+ regulatory T cells toward an antileukemia response Leukemia 22 1007 1017
22. P Kokhaei L Adamson M Palma 2006 Generation of DC-based vaccine for therapy of B-CLL patients Comparison of two methods for enriching monocytic precursors Cytotherapy 8 318 326
23. P Kokhaei A Choudhury R Mahdian 2004 Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL Leukemia 18 1810 1815
24. P Kokhaei M Palma L Hansson 2007 Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells Exp Hematol 35 297 304
25. P Kokhaei MR Rezvany L Virving 2003 Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL Leukemia 17 894 899
26. T Kollgaard SL Petersen SR Hadrup 2005 Evidence for involvement of clonally expanded CD8+ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation Leukemia 19 2273 2280
27. GD MacLean DW Miles RD Rubens 1996 Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide J Immunother Emphasis Tumor Immunol 19 309 316
28. DI Marks R Lush J Cavenagh 2002 The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation Blood 100 3108 3114
29. C Mayr D Bund M Schlee 2006 MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes Exp Hematol 34 44 53
30. C Mayr D Bund M Schlee 2005 Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes Blood 105 1566 1573
31. E Mikaelsson AH Danesh-Manesh A Luppert 2005 Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma Blood 105 4828 4835
32. MR Rezvany M Jeddi-Tehrani H Rabbani 2000 Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia Br J Haematol 111 230 238
33. MR Rezvany M Jeddi-Tehrani H Wigzell 2003 Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia Blood 101 1063 1070
34. JM Ribera N Vinolas A Urbano-Ispizua 1987 "Spontaneous" complete remissions in chronic lymphocytic leukemia: report of three cases and review of the literature Blood Cells 12 471 483
35. D Ridgway 2003 The first 1000 dendritic cell vaccinees Cancer Invest 21 873 886
36. M Schuler T Tretter F Schneller 1999 Autocrine transforming growth factor-beta from chronic lymphocytic leukemia-B cells interferes with proliferative T cell signals Immunobiology 200 128 139
37. S Siegel A Wagner D Kabelitz 2003 Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies Blood 102 4416 4423
38. CL Slingluff Jr GR Petroni GV Yamshchikov 2003 Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells J Clin Oncol 21 4016 4026
39. A Trojan JL Schultze M Witzens 2000 Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies Nat Med 6 667 672
40. WG Wierda MJ Cantwell SJ Woods 2000 CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia Blood 96 2917 2924
41. RH Vonderheide SM Domchek JL Schultze 2004 Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes Clin Cancer Res 10 828 839
42. RJ Vuylsteke BG Molenkamp HA Gietema 2004 Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma Cancer Res 64 8456 8460
43. R Yamanaka T Abe N Yajima 2003 Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial Br J Cancer 89 1172 1179
44. HW Ziegler-Heitbrock R Schlag D Flieger E Thiel 1989 Favorable response of early stage B CLL patients to treatment with IFN-alpha 2 Blood 73 1426 1430